The tweet was deleted by the author.
But we saved everything 🙂.
Vir Biotechnology has unveiled new positive data from the ongoing SOLSTICE Phase 2 trial. Participants taking the company's combination therapy for chronic hepatitis delta (CHD) demonstrated increased viral suppression of HDV RNA compared to those receiving monotherapy.
These findings, highlighted at the renowned JPM26 event, signify a substantial advancement in treatment options for hepatitis delta, potentially impacting future therapeutic strategies. Stakeholders are invited to learn more on January 14 through the provided link.
The positive momentum in Vir Biotechnology’s clinical portfolio follows strategic moves such as their recent partnership to expand access to hepatitis Delta treatment, detailed in the agreement with Norgine, which broadened the company's reach across Europe, Australia, and New Zealand. These developments collectively underscore Vir's commitment to advancing novel solutions for CHD and reshaping the therapeutic landscape.